Evidence map›Paper›PMID 33830991›Full record

ArticlePLoS neglected tropical diseases2021

Characterization and functional analysis of the proteins Prohibitin 1 and 2 in Trypanosoma cruzi.

Ana K Ibarrola-Vannucci, Luis M De Pablos, Lissette Retana-Moreira, Alberto Cornet-Gomez, Teresa Cruz-Bustos, Alejandro G Schijman, José L Ramírez, Susana Vílchez, Antonio Osuna

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. The ElusivePathogens (Basel, Switzerland) · 2023
    Review
  4. Ablation of theFrontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Ana K Ibarrola-VannucciInstituto de Biotecnología. Departamento de Parasitología, Grupo CTS183, Universidad de Granada, Spain.ORCID 0000-0001-8790-8916
Luis M De PablosInstituto de Biotecnología. Departamento de Parasitología, Grupo CTS183, Universidad de Granada, Spain.
Lissette Retana-MoreiraInstituto de Biotecnología. Departamento de Parasitología, Grupo CTS183, Universidad de Granada, Spain.
Alberto Cornet-GomezInstituto de Biotecnología. Departamento de Parasitología, Grupo CTS183, Universidad de Granada, Spain.ORCID 0000-0001-9378-8594
Teresa Cruz-BustosInstituto de Biotecnología. Departamento de Parasitología, Grupo CTS183, Universidad de Granada, Spain.ORCID 0000-0002-6976-4354
Alejandro G SchijmanLaboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Biología Molecular e Ingeniería Genética "Dr Héctor Torres" (INGEBI), Consejo Nacional de Ciencia y Tecnología (CONICET), Buenos Aires, Argentina.
José L RamírezBiotechnology Center, Instituto de Estudios Avanzados, Instituto de Biología Experimental, Universidad Central de Venezuela, Caracas, Venezuela.
Susana VílchezInstituto de Biotecnología. Departamento de Parasitología, Grupo CTS183, Universidad de Granada, Spain.ORCID 0000-0003-3729-4113
Antonio OsunaInstituto de Biotecnología. Departamento de Parasitología, Grupo CTS183, Universidad de Granada, Spain.ORCID 0000-0002-3818-1471
Universidad de Granada · ESConsejo Nacional de Investigaciones Científicas y Técnicas · ARInstituto de Estudios Avanzados · VE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChagas disease is the third most important neglected tropical disease. There is no vaccine available, and only two drugs are generally prescribed for the treatment, both of which with a wide range of side effects. Our study of T. cruzi PHBs revealed a pleiotropic function in different stages of the parasite, participating actively in the transformation of the non-infective replicative epimastigote form into metacyclic trypomastigotes and also in the multiplication of intracellular amastigotes. METHODOLOGY/PRINCIPAL

findingsTo obtain and confirm our results, we applied several tools and techniques such as electron microscopy, immuno-electron microscopy, bioinformatics analysis and molecular biology. We transfected T. cruzi clones with the PHB genes, in order to overexpress the proteins and performed a CRISPR/Cas9 disruption to obtain partially silenced PHB1 parasites or completely silenced PHB2 parasites. The function of these proteins was also studied in the biology of the parasite, specifically in the transformation rate from non-infective forms to the metacyclic infective forms, and in their capacity of intracellular multiplication. CONCLUSION/SIGNIFICANCE: This research expands our understanding of the functions of PHBs in the life cycle of the parasite. It also highlights the protective role of prohibitins against ROS and reveals that the absence of PHB2 has a lethal effect on the parasite, a fact that could support the consideration of this protein as a possible target for therapeutic action.

Indexed as

Life Cycle StagesAnimalsChagas DiseaseClustered Regularly Interspaced Short Palindromic RepeatsComputer SimulationMaleMiceMice, Inbred BALB CMicroscopy, Electron, ScanningProhibitinsProtozoan ProteinsRatsRats, WistarRepressor ProteinsTrypanosoma cruziPhb2 protein, mousePhb protein, ratProhibitinsProtozoan ProteinsRepressor Proteins

Identifiers

PMID33830991
PMCPMC8057595
OpenAlexW3149873736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.